Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ASCO 2014 CO-1686’

Post ASCO 2014, many journalists and commentators have hotly declared the third-generation EGFR inhibitor CO-1686 from Clovis Oncology to be a “loser.”

AstraZeneca have a competitor compound AZD9291 also in early stage development.  We’ve been keenly following both compounds on the blog over the past year.

While the Clovis share price has dropped, we are certainly not declaring Clovis CO-1686 to be a loser at ASCO 2014, nor are we declaring AZD9291 to be winner – with no median survival data mature yet, it’s far too soon to call it either way.

For this piece, we interviewed Dr Pasi Jänne (DFCI) who presented the AZD9291 data at ASCO and Dr Lecia Sequist (MGH) who presented the CO-1686 data. We also gained perspectives from Dr Ross Camidge (Univ of Colorado), who has participated in both trials.

You can login or sign up below to read why I think CO-1686 was not a loser at ASCO 2014.

Good morning from Chicago and the annual meeting of the American Society of Clinical Oncology (ASCO) where we are continuing our coverage of the meeting with a live blog from day 2 of the meeting.

As the day progresses we’ll be adding in tweets we want to share, short comments on sessions we attend (blog posts will follow later), and time-permitting excerpts of interviews. It’s an experiment, so bear with us, we hope it works and doesn’t distract too much from time spent gathering data and talking to people.

Subscribers can log in below.

error: Content is protected !!